Eris Lifesciences spurts after Q4 PAT skyrockets 200% YoY to Rs 282 cr
Mumbai, May 20 -- Total revenue from operations rose 7.26% to Rs 756.56 crore in Q4 FY26 over Q4 FY25.
Profit before tax (PBT) stood at Rs 159.41 crore in Q4 FY26, up 23.69% from Rs 128.87 crore recorded in the same quarter last year.
During the quarter EBITDA stood at Rs 274 crore, up 8% compared with Rs 252 crore posted in same quarter last year. EBITDA margin expanded to 36.2% in Q4 FY26 as against 35.8% in Q4 FY25.
Revenue from domestic branded formulation (DBF) business jumped 12% YoY to Rs 671 crore in Q4 FY26. The International Business fell 8% to Rs 86 crore in Q4 FY26.
The company declared an interim dividend of Rs 7.21 per fully paid-up equity share of Re 1 each (721%) for FY27. It has fixed Friday, May 29, 2026, as the reco...
Click here to read full article from source
इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया
हमे संपर्क करें.